title: Results after laparoscopic lysis of adhesions and placement of seprafilm for intractable abdominal pain.
abstract: BACKGROUND
  The surgical treatment of patients with chronic abdominal pain resulting from intraabdominal adhesions is controversial. We report our experience with treatment of this challenging patient population using laparoscopic lysis of adhesions (LOA) and placement of Seprafilm (Genzyme, Cambridge, MA, USA).
  
  
  METHODS
  The participants in this study were 19 consecutive patients (2 men and 17 women) who underwent laparoscopic LOA and placement of Seprafilm between July 1998 and July 2001. Patients with abdominal pain resulting from irritable bowel syndrome, hernias, or endometriosis were excluded. The patients had undergone a mean of 6.4 previous abdominal procedures (range, 1-14) and 2.3 previous LOAs (range, 0-10). They had experienced chronic, intractable abdominal pain for at least 4 months (range, 4-180). Eight patients had preoperative obstructive symptoms.
  
  
  RESULTS
  A completely laparoscopic procedure was used to treat 16 patients, whereas the procedure for 3 patients was converted to open surgery because of dense adhesions. Perioperative complications included two patients in whom enterocutaneous fistulae developed and one patient with intraabdominal hematoma. At follow-up (mean, 9.6 months; range, 1-32 months), 14 patients (73.7%) had completely discontinued all pain medications. At this writing, 12 of these patients are completely symptom free. Two patients are taking nonsteroidal antiinflammatory drugs (NSAIDs) as needed, and three patients require round-the-clock narcotics. Three patients were readmitted with small bowel obstruction, which was managed nonoperatively. One patient had diagnostic laparoscopy for recurrent pain 6 months postoperatively, but had no adhesions.
  
  
  CONCLUSIONS
  Chronic intractable abdominal pain is relieved in most patients via this approach. Repeat laparoscopy in two patients showed no intraabdominal adhesions. Laparoscopic LOA and placement of Seprafilm is an excellent approach to this challenging patient population with symptoms caused by intraabdominal adhesions.
authors.affiliation: Department of Surgery, Vanderbilt University Medical Center, D5203 MCN, Nashville, TN 37232, USA. leena.khaitan@vanderbilt.edu
authors.forename: L
authors.initials: L
authors.lastname: Khaitan
authors.forename: S
authors.initials: S
authors.lastname: Scholz
authors.forename: H L
authors.initials: HL
authors.lastname: Houston
authors.forename: W O
authors.initials: WO
authors.lastname: Richards
mesh_terms: D034861:Abdominal Wall / Q000601:surgery*; D000328:Adult; D000368:Aged; D001672:Biocompatible Materials / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006820:Hyaluronic Acid; D010535:Laparoscopy; D008297:Male; D008567:Membranes, Artificial; D008875:Middle Aged; D010148:Intractable Pain / Q000209:etiology / Q000517:prevention & control*; D012008:Recurrence; D012086:Reoperation; D000267:Tissue Adhesions / Q000150:complications / Q000628:therapy*
chemical_list: D001672:Biocompatible Materials; D008567:Membranes, Artificial; C118198:Seprafilm; D006820:Hyaluronic Acid